1 financial community briefing september 2006 2 nicox participants to the senior management team michele garufi chief executive officer maarten beekman vp clinical development eric castaldi damian marron corporate ennio ongini research staffan stromberg drug investor relations karl hanks com 33 497152203 3 agenda introduction m product generation e naproxcinod hct 3012 need for safer nsaids market overview and positioning d phase plan s ncx 4016 re directing novel insulin sensitizer treat type diabetes no donating statins 6560 a new nitric oxide statin derivative status of ongoing alliances review moving from an r&d company fully integrated pharma 4 transformation increasing headcount in line with activities our advanced programmes partnerships internal finance future growth employee count 0 10 20 30 40 50 60 70 80 90 100 dec june 2005 5 one
